RxDoctor Payments Data

Iesha Bell

Family · Streetsboro, OHNPI 1881139897

Payments from drug & device makers

$938in general payments, 2019–2025

Across 40 payments — averaging $23.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$266
  • Novo Nordisk$227
  • Exact Sciences$108
  • AbbVie$72
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$54
  • GSK$37
  • plus $173 from 8 others

What the payments were for

  • Food & beverage$938100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$938 in reported general payments places this provider in the 70th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$18,916
Medicare patients
101
Services billed
307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin21$29,753
NuedextaDextromethorphan Hbr/Quinidine12$19,634
OzempicSemaglutide13$16,038
EliquisApixaban13$12,384
MounjaroTirzepatide11$11,025
SymbicortBudesonide/Formoterol Fumarate24$6,511
Albuterol Sulfate HfaAlbuterol Sulfate79$1,653
Wixela InhubFluticasone Propion/Salmeterol13$1,582
Ventolin HfaAlbuterol Sulfate25$1,405
BreynaBudesonide/Formoterol Fumarate17$1,221
Omeprazole69$1,170
Gabapentin80$1,130
Atorvastatin Calcium104$753
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$747
Metoprolol Succinate48$725

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$14$29,75321 claims
Novo NordiskOzempic$227$16,03813 claims
Lilly USA, LLCMounjaro$30$11,02511 claims
AstraZenecaSymbicort$266$6,51124 claims
AbbVieSynthroid$72$69018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,812 family providers in Ohio.

Other family in Streetsboro

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →